Market Risers: KEFI Minerals plc, GlaxoSmithKline plc, AstraZeneca plc, Burberry Group plc, Compass Group plc & Halma plc

KEFI Minerals
[shareaholic app="share_buttons" id_name="post_below_content"]

The share price for KEFI Minerals plc found using EPIC: LON:KEFI has risen 5.76% or 0.08 points during the course of today’s session so far. Market buyers have remained positive during the session. The high for the period has reached 1.57 and hitting a low of 1.4. The number of shares traded by this point in time totalled 1,059,942 whilst the daily average number of shares exchanged is just 2,482,760. The 52 week high price for the shares is 5 which comes in at 3.52 points difference from the previous close and the 52 week low at 1.37 which is a variance of 0.11 points. KEFI Minerals plc has a 20 SMA of 1.66 and the 50 day simple moving average now of 1.91. This puts the market capitalisation now at £8.10m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for KEFI Minerals plc being recorded at Thursday, November 15, 2018 at 11:34:41 AM GMT with the stock price trading at 1.56 GBX.

 

The trading price for GlaxoSmithKline plc with company EPIC: LON:GSK has risen 2.58% or 39.6 points throughout today’s trading session so far. Investors seem confident throughout the trading session. The period high has peaked at 1578.6 while the low for the session was 1536.4. The total volume of shares exchanged through this period comes to 3,067,212 with the daily average traded share volume around 10,116,732. A 52 week share price high is 1631.13 some 98.53 points difference from the previous close and the 52 week low at 1179.39 which is a variance of 353.21 points. GlaxoSmithKline plc has a 20 day moving average of 1551.44 and now its 50 day moving average now of 1530.56. The market capitalisation currently stands at £76,882.82m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for GlaxoSmithKline plc being recorded at Thursday, November 15, 2018 at 12:03:41 PM GMT with the stock price trading at 1572.2 GBX.

 

The stock price for AstraZeneca plc company symbol: LON:AZN has climbed 2.06% or 129.11 points during the course of today’s session so far. Market buyers have remained positive throughout the session. The high for the period has reached 6432.48 dropping as low as 6278.31. The volume total for shares traded up to this point was 793,809 with the daily average traded share volume around 2,711,143. The 52 week high is 6432.48 equating to 159.48 points in difference to the previous days close of business and a 52 week low sitting at 4544.5 is a variance of 1728.5 points. AstraZeneca plc has a 20 SMA of 6023.85 and now its 50 day moving average now of 5886.2. The market capitalisation currently stands at £79,131.47m at the time of this report. All share prices mentioned for this stock are traded in GBX. Mcap is measured in GBP. This article was written with the last trade for AstraZeneca plc being recorded at Thursday, November 15, 2018 at 12:03:33 PM GMT with the stock price trading at 6402.11 GBX.

 

The trading price for Burberry Group plc ticker lookup code: LON:BRBY has risen 1.1% or 19.5 points during the course of today’s session so far. Traders have stayed positive during the session. Range high for the period so far is 1816 and hitting a low of 1763.5. The total volume of shares traded by this point was 443,776 while the daily average number of shares exchanged is 2,993,621. The 52 week high for the share price is 2338 which is 561.5 points different to the previous business close and a 52 week low sitting at 1481.5 is a variance of 295 points. Market capitalisation is now £7,309.98m at the time of this report. The currency for this stock is Great British pence.Market cap is measured in GBP. This article was written with the last trade for Burberry Group plc being recorded at Thursday, November 15, 2018 at 12:03:01 PM GMT with the stock price trading at 1796 GBX.

 

Stock in Compass Group plc with company EPIC: LON:CPG has increased 1.9% or 30 points in today’s trading session so far. Traders are a positive bunch during the session. The periods high has already touched 1617 meanwhile the session low reached 1574. The volume total for shares traded up to this point was 1,258,210 while the daily average number of shares exchanged is 4,242,596. The stock 52 week high is 1722 about 145.5 points difference from the previous close and the 52 week low at 1396.5 a difference of some 180 points. Compass Group plc now has a 20 simple moving average of 1545.63 with a 50 day moving average now of 1601.68. This puts the market cap at £24,972.82m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for Compass Group plc being recorded at Thursday, November 15, 2018 at 12:03:34 PM GMT with the stock price trading at 1606.5 GBX.

 

Stock in Halma plc company symbol: LON:HLMA has stepped up 2.39% or 31 points during today’s session so far. Market buyers are a positive bunch throughout the session. The periods high figure was 1330 dropping as low as 1294. The number of shares traded by this point in time totalled 178,435 with the daily average number around 1,457,285. The stock 52 week high is 1507.97 some 208.97 points difference from the previous days close and the 52 week low at 1136 which is a difference of 163 points. Halma plc now has a 20 simple moving average of 1323.55 and now its 50 day moving average of 1370.3. This puts the market cap at £4,963.98m at the time of this report. The share price is in Great British pence. Mcap is measured in GBP. This article was written with the last trade for Halma plc being recorded at Thursday, November 15, 2018 at 12:02:07 PM GMT with the stock price trading at 1330 GBX.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials.
GSK reports success in phase III trial of Zejula and Jemperli for advanced ovarian cancer, achieving significant progression-free survival improvement.
GSK's Jemperli receives FDA Breakthrough Therapy Designation for treating locally advanced dMMR/MSI-H rectal cancer, expediting crucial development.

Search

Search